mammogen

Mammogen Taps Life Sciences Leadership Architect, Denise "DeeDee" DeMan, as Chairwoman of the Board of Directors

Mon, 30 Jun 2025 21:43:58 GMT

Renowned global builder of boards and executive teams aligns with leading women's health innovator, signaling next phase of commercial growth

NEWPORT BEACH, Calif., June 30, 2025 /PRNewswire/ -- Mammogen, a women-built and women-led predictive health company redefining what's possible in early disease detection, today announced the appointment of Denise "DeeDee" DeMan as Chairwoman of its Board of Directors.

DeMan, Founder, Chair, and CEO of Bench International, is one of the most respected leadership architects in global life sciences. With more than five decades of experience placing board directors, chairpersons, and C-level executives for some of the world's most successful and enduring healthcare companies, DeMan has built the leadership teams behind healthcare's most transformative innovations and industry-defining growth stories. Through initiatives such as Bench's acclaimed Bank of Women®, DeMan has helped organizations unlock the power of inclusive governance and executive excellence, aligning with Mammogen's commitment to having women's voices represented at every level of the company.

Her appointment reflects Mammogen's evolution from a research-stage innovator to a clinical-stage company preparing for commercialization, as it advances its blood-based early detection test for breast cancer towards market launch.

Mammogen's flagship product, genTRU™, is designed to detect breast cancer at its earliest and most treatable stages, focusing on quality-of-life preservation. The genTRU™ assay has demonstrated over 99% sensitivity and 89% specificity for Stage I disease, supported by several peer-reviewed publications and extensive clinical validation.

"Mammogen combines validated science, disciplined execution, and purpose-driven leadership—qualities that define the companies that change clinical landscapes and build commercial titans," said DeMan. "I've spent my career guiding organizations from inflection to impact, and it's rare to see this level of readiness and rigor at such a formative stage. I'm honored to serve as Chairwoman as we guide Mammogen into its next era of growth, and I'm committed to ensuring its leadership and governance are as differentiated as its science."

With pivotal trials underway, the company is preparing for commercialization as the world's first and most accurate targeted screening test for breast cancer, addressing an urgent unmet need for over 25 million U.S. women currently at-risk based on Mammography Quality Standards Act (MQSA) Guidelines.

"DeeDee's decision to join Mammogen at this critical juncture sends a clear message: we are building for scale, staying true to science, and ready to deliver paradigm-shifting value at a time when the market is demanding exactly that," said Elizabeth Cormier-May, CEO of Mammogen. "Her expertise in building governance and leadership for companies that endure is invaluable as we prepare for what's next."

As Chairwoman, DeMan will lead Mammogen's board governance strategy and support the company in strengthening its industry position as it accelerates towards this next stage of growth.

Media Contact
katherine@mammogen.bio

About Mammogen
Mammogen is a predictive health company pioneering the future of women's health diagnostics. Its flagship product, genTRU™, is a first-in-class blood-based assay with best-in-class accuracy for early detection of breast cancer, particularly in Stage I disease. Mammogen's mission is to preserve quality of life through earlier, more accessible detection powered by cutting-edge science. The company is proudly women-built, women-led, and purpose-driven. Learn more at www.mammogen.bio .

About Bench International
Bench International is the longest-serving woman-founded executive search firm in life sciences and healthcare. For over 50 years, Bench has built and advised boards and C-suites for many of the industry's most innovative and successful companies. With a 98% project completion rate and a track record of more than $150 billion in client exits, Bench specializes in executive search, board services, talent mapping, gap analysis, and interim and fractional leadership through Bench On Demand. Clients benefit from a global network, deep domain expertise, and a relentless focus on leadership that drives innovation, growth, and value. Learn more at www.benchinternational.com .

S2E18: Early Cancer Detection, Reimagined. Don't Be Dense, Get Checked with Liz Cormier-May, CEO of Mammogen

Fri, 25 Oct 2024 19:51:21 GMT

Did you know that mammograms have remained virtually unchanged since their invention in 1913? It's no wonder they feel archaic!

In honor of Breast Cancer Awareness Month , Dr. Tara and Gina Simm welcome Liz Cormier-May , CEO of Mammogen , to the iHeartRadio studio. As a chemist and leader in the field, Liz is driving innovation in breast cancer detection, making it early, affordable, and accessible .

And here's the exciting part: a simple blood test for breast cancer detection could be available as early as next year!

Tune in to find out how this groundbreaking development will change the game in cancer detection , what the categories are for dense breasts AND what the heck a Bi-Rads category is!

Mammogen is currently accepting patients for their clinical trial. Please visit mammogen.bio to sign up!

Listen to the full episode here:

https://www.buzzsprout.com/2307750/episodes/15954302

Safe & Green Holdings Corp. Taps Global Life Sciences & Diagnostics Executive, Elizabeth Cormier-May, to Join Company Board of Directors

Wed, 11 Jan 2023 01:20:45 GMT

Elizabeth Cormier-May, CEO of Mammogen, Inc., and Dragonfly Data Ventures, Partner and CCO of IV BioHoldings, joins SGH Corp. board of directors to provide expertise and strategy to the Company’s medical arm

JACKSONVILLE, Fla., January 09, 2023--(BUSINESS WIRE)--Safe & Green Holdings Corp. (NASDAQ: SGBX) ("Safe & Green Holdings" or the "Company"), a leading developer, designer, and fabricator of modular structures, announced today that the Company is adding diagnostics, life sciences, and biotechnology leader Elizabeth Cormier-May to its board of directors.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230109005294/en/

(Photo: Business Wire) Elizabeth Cormier-May

The addition comes at a time in which the Company is growing its medical footprint with working plans in place to expand within the diagnostic healthcare space, via Safe & Green Holdings’ sustainable, modular solutions.

Elizabeth Cormier-May began her career as a medicinal chemist, specializing in early discovery oncology at the Novartis institute for Biomedical Research. Ms. Cormier-May currently serves as CEO and Board Director of Mammogen, Inc., as well as the Chairman of the Board, Co-Founder, and CEO of Dragonfly Data Ventures. Mammogen, Inc. is a women’s health diagnostics company focused on the noninvasive detection of disease in its earliest stages. Mammogen is one of 3 companies within the IV BioHoldings (IVBH) ecosystem, where Ms. Cormier-May also serves as the SVP and Chief Commercial Officer. IVBH is a privately held bio-innovation platform that seeks to conceive, create and develop first-in-category precision health technologies and companies that radically improve detection, diagnosis and treatment of disease.

Dragonfly Data Ventures, a privately held company, is building a Data Influence PlatformTM designed to redefine personal wellness by allowing wearable and smartphone users to focus on the persona most important to them, to establish the goals most critical to their success, which enables Dragonfly to give them the personalized tools to extrapolate clinical, wellness and financial value.

"We couldn’t be happier to add Elizabeth Cormier-May to our Board of Directors," Paul Galvin, Chairman and CEO of Safe & Green Holdings Corp. explained. "She is a well-rounded bio-tech professional with a fantastic blend of science and executive experience. As we seek to grow our medical segment, we believe Ms. Cormier-May is a perfect team member to have, with vast experience in the life sciences and biopharma markets and a distinct focus on the critical disruption necessary for meaningful progress."

In January of 2022, Ms. Cormier-May was named Biotechnology CEO of the year for Mammogen, Inc., in the 2021 Global Corporate Excellence Awards, by Business Worldwide Magazine. Ms. Cormier-May was awarded for her visionary approach and mission to "shatter complacency and radically improve the way women's diseases are detected, diagnosed and treated," according to Business Worldwide Magazine.

"In a market and landscape that so desperately needs more efficient, sustainable, and cost-friendly solutions for the patients we all collectively serve, I could not be prouder to be joining the Board of Directors at Safe & Green Holdings Corp," stated Cormier-May. "I very much look forward to working with the incredible team to shape and help grow their already impressive capabilities within the medical space during a time when critical disruption is so needed."

Ms. Cormier-May received her B.A. in organic chemistry from Wheaton College and attended Northeastern University’s chemical biology and organic chemistry program. She resides in Central Connecticut with her family.

About Safe & Green Holdings Corp.

Safe & Green Holdings Corp., a leading modular solutions company, operates under core capabilities which include the development, design, and fabrication of modular structures, meeting the demand for safe and green solutions across various industries. The firm supports third party and in-house developers, architects, builders and owners in achieving faster execution, greener construction, and buildings of higher value. Safe and Green Development Corporation is a leading real estate development company. Formed in 2021, the company focuses on the development of sites using purpose built, prefabricated modules built from both wood & steel, sourced from one of Safe & Green Holdings factories and operated by SG Echo. For more information, visit www.safeandgreenholdings.com.

Safe Harbor Statement

Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding the Company growing its medical footprint, the Company’s plans to expand within the diagnostic healthcare space via SGH Corp’s sustainable, modular solutions and the expected contribution of Ms. Cormier-May to the Company. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company’s ability to grow its medical footprint and expand within the diagnostic healthcare space via its sustainable, modular solutions, the contribution of Ms. Cormier-May to the Company, the Company’s ability to expand within various verticals as planned, the Company’s ability to position itself for future profitability, the Company’s ability to maintain compliance with the NASDAQ listing requirements, and the other factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230109005294/en/

Mammogen Inc. CEO Elizabeth Cormier-May Wins Illustrious Award with Business Worldwide Magazine

Sun, 23 Jan 2022 22:22:45 GMT

LONDON, Jan. 19, 2022 /PRNewswire/ -- Liz Cormier-May of Mammogen was named Biotechnology CEO of the Year – USA in the 2021 Global Corporate Excellence Awards.

The awards, run by Business Worldwide Magazine, seek to identify and honor the most respected companies and C level executives in the world. The aim is to reward outstanding performance, innovation, and ethics across international business and finance communities, covering a vast range of sectors. Liz Cormier-May won the award for her visionary approach, which is changing the face of healthcare for women all over the world.

Mammogen uses a combination of data, technology, science and personal experience to challenge the status quo. Liz is an outspoken leader in her field, and her mission is to shatter complacency and radically improve the way women's diseases are detected, diagnosed and treated.

Breast cancer affected over 2.3 million women globally in 2020, resulting in 685,000 deaths. Mammogen is at the forefront of emerging technologies that radically improve early detection rates, potentially saving millions of lives in the process. The company also empowers women in all areas of their lives, starting new conversations about the fears, anxiety, depression, marital challenges and body shame issues that come hand in hand with breast cancer.

Liz began her career as a medicinal chemist specialising in early discovery oncology at the Novartis institute for Biomedical Research. For almost 20 years, she has been developing new markets, products and companies, with one shared goal – to introduce novel options and technologies that enhance patient experiences and save lives.

As well as leading Mammogen, Liz is also the CCO of IV Bioholdings; a bio innovation studio that conceives, creates and develops first-in-category RNA bio platforms which radically improve the detection, diagnosis and treatment of disease. To date, IV BioHoldings has created three first in class new biopsy programs, eight clinical stage diagnostics, and has discovered over two hundred novel RNA biomarkers. Together these have the potential to save over a billion lives around the world.

To find out more about Mammogen's innovative, life saving technologies, visit https://www.mammogen.bio

Further information on the individuals and companies which picked up titles in the Global Corporate Excellence Awards 2021, can be found at: https://www.bwmonline.com/2021-global-corporate-excellence-awards-winners/

About Business Worldwide Magazine

Business Worldwide Magazine is the leading source of business and dealmaker intelligence throughout the world. Our quarterly magazine and online news portal enable an established audience of corporate dealmakers to track the latest news, stories and developments affecting the international markets, corporate finance, business strategy and changes in legislation. This readership includes of CEO/CFO - Banks, Corporate Lawyers and Venture Capital/Private Equity Companies to name a few.

Mammogen and Brilliantly Continue their Commitment to the Breast Cancer Community with Brilliantly Warm Giveaway

Tue, 11 Jan 2022 15:43:47 GMT

Partnership between female-led women’s healthcare companies will give away 50 pairs of Brilliantly Warm wearable bra inserts - the world’s first-ever wearable designed specifically for women after reconstructive surgery - to the breast cancer community

PROVIDENCE, R.I.--( BUSINESS WIRE )-- Brilliantly and Mammogen, Inc. – two female-led women’s healthcare companies centered around breakthrough technologies designed to solve unmet clinical needs in the breast cancer space – announced their partnership in October. The companies are working on compiling a coffee table book, detailing the comprehensive journey of breast cancer with stories, letters, photos, and recipes. Brilliantly and Mammogen also announced that they are working together to create exercise routines and videos that accommodate the changes in physiology and mindset after breast cancer.

To demonstrate their collective commitment in 2022, Brilliantly and Mammogen today announced that Mammogen is sponsoring the giveaway of 50 Brilliantly Warm wearable bra inserts, the first-ever wearable designed specifically for women who have had breast reconstruction surgery. Individuals can sign up for consideration at home.brilliantlywarm.co/brilliantly-warm-giveaway with the give away limited to 50 participants. Participants will be asked to also help the companies gather further information on the product experience, and their own journey, to help inform future product releases.

Brilliantly Warm , Brilliantly’s flagship product, is the first-ever warming wearable designed by and for women who have had breast reconstruction surgery. Brilliantly Warm, a discreet, rechargeable, heated bra insert, was designed for women who have had breast implant reconstruction and, as a result, experience an overwhelming sense of coldness. The Brilliantly Warm iOS and Android app allows users to manage the temperature of their device with ease and in any environment – the office, outdoors, or at a social gathering or event.

“I’m excited to partner with Mammogen – working together, we can leverage our collective resources across the continuum of care for breast cancer patients, to help women like us build community and find answers to some of the most important and personal questions,” said Kristen Carbone, founder of Brilliantly.

“We stated our from-end-to-never-end commitment to our patient community on day one, and that has never waivered. This is a powerful way for us at Mammogen to contribute to our community while we are focusing on the clinical development of our genTRUTM-breast program, a suite of best-in-class early detection tests for breast cancer,” commented Elizabeth Cormier-May, CEO of Mammogen.

Dr. Monique Gary is a board certified, fellowship-trained Breast Surgical Oncologist and Medical Director of the Grand View Health/Penn Cancer Network Cancer Program in Sellersville, PA, where she also serves as director of the Breast Program. As the founder of Touch, The Black Breast Cancer Alliance , she will partner with The Breasties , and, together, they will help oversee distribution of Brilliantly Warm to ensure the products reach a diverse group of women in the breast cancer community.

“We are thrilled to be partnering with Brilliantly and Mammogen to gather such important clinical and patient data,” added Dr. Gary “We are committed to finding ways to innovate and close the gaps in the continuum of care, particularly post remission. Chronic coldness is a real problem for our patients, and we look forward to securing an improved understanding of the patient experience with Brilliantly Warm.”

About Brilliantly

Brilliantly helps women with the transition from confronting breast cancer to embracing life through innovative products, thoughtful content, and relevant services. The company has recently released their flagship technology, Brilliantly Warm, the first-ever wearable designed specifically for women who have had breast reconstruction surgery. For more information visit www.brilliantly.co .

About Mammogen

Mammogen is a female-led biotechnology company focused on meaningfully improving the detection, diagnosis and treatment of women’s health-related diseases, and creating an end-to-never-end community for women around the world. Mammogen is centered around its proprietary genTRUTM liquid biopsy platform. The company’s flagship genTRU-breastTM program leverages novel messenger RNA (mRNA) technology to non-invasively detect and diagnose breast cancer. The genTRUTM offering is positioned to unlock regular and reliable screening for millions of women around the world and eliminate many negative, invasive biopsy procedures. The company’s proprietary multi-gene expression signature for breast cancer detection has been extensively validated in blood, as well as saliva, and has shown statistical significance towards providing measurable improvement upon current standards of care. Mammogen’s product pipeline consists of an array of non-invasive prognostics and diagnostics for additional diseases that affect some-, mostly-, or only-women. For more information visit www.mammogen.bio .

Mammogen Touts Growing List of 2021 Awards and Recognitions for its Work in Women’s Health and Breast Cancer Diagnostics

Thu, 28 Oct 2021 23:34:18 GMT

After recent partnership announcements, female-led women’s health startup, Mammogen, showcases growing list of 2021 awards and recognitions

ALISO VIEJO, Calif.--( BUSINESS WIRE )--Mammogen, a female-led women’s health company, today has announced a list of 2021 awards and recognitions for its work in women’s health and, more specifically, breast cancer.

Mammogen named “ Best Breast Cancer Detection Technology Company - US ” by Global Health and Pharma Magazine (GHP)
Mammogen named “ 1 of 5 Biotech Companies to Watch in 2021 ” by The Silicon Review®
Mammogen selected as one of two women’s health companies featured throughout the 2021 American Association of Clinical Chemistry (AACC) Annual Scientific Meeting & Clinical Lab Expo in Atlanta, GA

The awards and recognitions come off the heels of two recent partnership announcements. The first being a strategic lab partnership with P4 Diagnostix® (P4) that will cover all clinical development and validation of Mammogen’s genTRU-breastTM liquid biopsy diagnostic platform, a proprietary RNA-based technology for early detection testing and patient stratification post-imaging.

“Our purpose-built partnership model at Mammogen places us in a unique position to enter clinical development of our first-in-class breast cancer diagnostics with a level of speed and efficiency that the industry has never before experienced,” stated Elizabeth Cormier-May, CEO of Mammogen. “In addition to bypassing the time and cost typically associated with organically building a lab, sales force, and regulatory team, the partnership with P4 provides us with nearly 20 years of diagnostic commercialization expertise, seven CLIA certified labs and defined channels to market into women’s health,” Cormier-May continued.

The second partnership, announced intentionally during breast cancer awareness month and the one-year anniversary of Mammogen’s incorporation, is a comprehensive collaboration with Brilliantly, another female-led company helping women transition from confronting breast cancer to embracing life through innovative products, thoughtful content and relevant services. The collaboration will equip breast cancer previvors and survivors with the tools they need to live empowered lives through an exclusive book project and a corrective exercise program.

“The collaboration with P4 and Brilliantly is a clear demonstration of our commitment to ensuring the quality of our clinical diagnostic solutions and ensuring that we address all of the needs from the community that we serve, for all women, from end-to-never-end,” said Cormier-May.

According to management, the company plans to announce data from its upcoming clinical studies in 2022 and plans to share additional details related to the Brilliantly projects over the coming months.

About Mammogen

About P4 Diagnostix®

P4 Diagnostix® is a network of several nationally recognized testing and diagnostic facilities integrated into one unified lab services organization, offering clients unparalleled access to connectivity, healthcare resources and consultative partnerships. P4 is made up of these industry-leading companies: Theranostix, Long Island Pathology, Platinum Pathology, Metamark Laboratories and P4 Clinical. P4's progressive integration of diagnostic testing and office workflow is rooted in partnership with VitalAxis, an industry-leader in the delivery of healthcare informatics. For more information visit www.p4dx.com .

About Brilliantly

Mammogen and Brilliantly Combine Forces to Advance Community Efforts for Breast Cancer Previvors and Survivors

Fri, 15 Oct 2021 13:50:22 GMT

Female-led women’s health companies announce comprehensive partnership designed to empower breast cancer community

ALISO VIEJO, Calif. & PROVIDENCE, R.I.--( BUSINESS WIRE )--Brilliantly and Mammogen, Inc., two female-led women’s health companies centered around breakthrough technologies designed to solve unmet clinical needs associated with breast cancer, announce a comprehensive partnership expected to improve quality of care for the breast cancer community, both inside and outside of the physician’s office.

The collaboration, which will equip breast cancer previvors and survivors with the tools they need to live empowered lives, is an intentional step towards each company’s commitment to advancing every aspect of women’s health, beyond traditional product-related decisions.

“Over my nearly twenty years in the diagnostics industry, it has always baffled me that companies never invest time or resources to empower the communities that they serve,” said Elizabeth Cormier-May, CEO of Mammogen. “Whether you’re at a higher risk of developing breast cancer based on genetics or family history, newly diagnosed, or past your five-year mark, there’s no shortage of mental, emotional and physical anguish associated with this disease. At Mammogen, we work tirelessly to innovate around the clinical and the personal experience, not only because it makes great business sense; but, most importantly, because it is the right thing to do. We know that end-to-end care is good but creating an end-to-never-end community is far more powerful, and our partnership with Brilliantly brings us a step closer to fulfilling that mission.”

The comprehensive collaboration will first include an exclusive book project which will be a collection of short stories, interviews and creative writing pieces representing hundreds of voices that address everything from talking about hereditary risk with children to sexual dysfunction to career changes.

“For many of us, the aftermath of surgical intervention and treatment has simply been called ‘the new normal’, yet it doesn’t feel normal at all,” stated Kristen Carbone, Founder and CEO of Brilliantly and breast cancer previvor. “How can we feel normal again? Where do we even start? The issues faced by this community are so multifaceted, I struggle to think of even a single part of everyday life that isn’t impacted in some way by an experience with breast cancer,” continued Carbone.

The second initiative is a corrective exercise program that will include various workout modalities to help regain strength and mobility safely for women who’ve had breast surgery and/or treatment. Specific exercise routines for breast cancer patients, survivors, and previvors have been proven to improve quality of life as well as decrease mortality.1 This collaboration between Mammogen and Brilliantly will ensure that all women have access to appropriate exercise routines throughout their journeys.

Both initiatives, while currently underway, will officially kick off in early 2022, upon successfully securing necessary sponsorship.

About Mammogen

About Brilliantly

JNCI J Natl Cancer Inst, 2021, Vol. 113, No. 1

SPOTLIGHT INTERVIEW: LIZ CORMIER-MAY, CEO, MAMMOGEN, INC.

Fri, 08 Oct 2021 03:03:21 GMT

About Elizabeth Cormier-May

Liz has been in the biotechnology industry for nearly 20 years, with a focus on early start-ups and company creation. She started her career as a medicinal chemist for Novartis Institute for Biomedical Research, working in early discovery oncology. She quickly realized that her ability to create meaningful change in this space was limited, and she pivoted to creating novel markets within diagnostics, where she was able to have greater impact on patients’ quality of care and individualized journey.

Liz has spent the majority of her career in oncology and women’s health. She has focused on creating new markets, launching novel products, and building industry-disrupting companies from the ground up. Currently, she is Chairman of the Board, Co-Founder, President and CEO of her digital health start-up, Persona Health, Inc. and CEO and Board Director of an innovative women’s health, diagnostic start-up, Mammogen, Inc. Liz takes a novel approach to both product development and commercialization, always with an eye towards patient empowerment.

An entrepreneur at heart, she has found innovative ways to simultaneously add value to her companies’ end-users, as well as her investors. Liz is fueled by the notion that there is a patient, someone’s loved one, at the end of every decision she makes.

About Mammogen

Mammogen is a female-led biotechnology company focused on meaningfully improving the detection, diagnosis and treatment of women’s health-related diseases, and creating an end-to-never-end community for women around the world. Mammogen is centered around its proprietary genTRU™ liquid biopsy platform. The company’s flagship genTRU breast™ program leverages novel messenger RNA (mRNA) technology to non-invasively detect and diagnosis breast cancer. The genTRU breast™ offering is positioned to unlock regular and reliable screening for millions of women around the world and eliminate many negative invasive biopsy procedures. The company’s proprietary multi-gene expression signature for breast cancer detection has been extensively validated in blood, as well as saliva, and has shown statistical significance towards providing measurable improvement upon current standards of care. Mammogen’s product pipeline consists of an array of non-invasive prognostics and diagnostics for additional diseases that affect some-, mostly-, or only-women. For more information visit www.mammogen.bio .

Medical Travel & Digital Health News (MTDHN): Tell us how you got interested in this incredibly important field.

Liz Cormier-May (LCM): I started as a medicinal chemist for Novartis Pharmaceuticals working in early discovery oncology. One of the programs that I worked on happened to be breast cancer.

I’ve always had a distinct passion for women’s health, particularly fighting breast cancer, as there is still so much work to be done in these areas.

Now, especially in a time when women are making the majority of household health decisions and handling the majority of the family’s finances, there’s no reason why a company shouldn’t put resources towards women’s health.

Women are far more likely to take a medical action, handle logistics and pay bills.

This is a unique time as we come out of the pandemic with shifting dynamics. All the stars are aligning and women are finding their voice, speaking up and demanding better healthcare. They want companies that are dedicated to improving their outcomes.

It’s just a really special point in time for Mammogen to be debuting with novel partners, novel products, and really focusing all of our attention on creating products that serve women.

MTDHN: Why is this a global message?

LCM : Very simply: It’s a global message because women are across the globe. Women make up half the world’s population meaning half of our world is not served in the manner they deserve to be served.

Though women’s health is underserved in the U.S., it’s grossly underserved in other parts of the world. There are still areas where women don’t even have access to healthcare and that has to change.

One of the things that makes Mammogen’s technology so exciting is that all our tests are liquid biopsy based, which means we are validating our easily administered tests on saliva, blood, and biofluids that are inexpensive to test and easy to ship around the world.

Imagine a time where women and other people around the world who may not have access to healthcare can order a saliva-based test to see if they have a breast cancer.

MTDHN: Tell us the role of diagnostics in this fast-emerging digital world.

LCM: D igital diagnostics are especially important and of interest in the women’s healthcare market.

The world is a busy place. We are 100% engaged with our mobile devices, and there is absolutely no reason why diagnostics can’t conform to this new era of digitalization, especially in a world where telehealth has taken an enormous jump over the last 18 months.

Diagnostics are exceedingly important. As hard as scientists in the medical community are working to eradicate cancer, I do not think that will happen in our lifetime. Our best bet is to get ahead of it and detect cancer in its earliest stages.

Early detection is important because:

It allows us to get information to women at a point where they can intervene in a more meaningful manner. For example, early detection of breast cancer will create the opportunity to preserve eggs or start family planning for millions of women who, all too often, do not have that opportunity today.
When women under 40 get breast cancer, they often don’t have time to even think about setting up an appointment with a reproductive endocrinologist — they just start treatment. A lot of this is because women under 40 are often diagnosed with more aggressive forms of the disease, so time is truly of the essence.

The earlier we can catch this disease, the more time and options we give our patients. That is what this is all about.

MTDHN: How does digitized care impact this space?

LCM: When we combine that early detection message with the digitalization of medicine, we can think about easier ways to accomplish these goals. Maybe individuals can order a test from their mobile device, get their results on their mobile device or get an app that integrates with their Apple Health device.

All these things are coming together in a way that allows healthcare to be a part of one’s everyday life, not a once-a-year trip to see a physician.

MTDHN: Tell us about the role of artificial intelligence (AI) and machine learning in this brave new world of diagnostics.

LCM: It’s very important — but there are limitations. It is not a magic fix to everything.

When used properly, AI and machine learning allow us to comb through millions of data points in a way that the human brain could never do. Data gives us a more comprehensive view of the system biology behind a certain disease state.

For example, at Mammogen, our technology platform is exclusively licensed through a company called Liquid Biosciences . Their technology is based upon artificial intelligence and machine learning, but what makes it incredibly unique is that it uses evolutionary computing.

This means that it incorporates millions of clinical datapoints, generates millions and millions of corresponding algorithms and puts them into an ecosystem where they evolve, just like humans have done. These algorithms mate, mutate and migrate. This process is like natural selection, but probably more appropriately natural de-selection. All of the algorithms and biomarkers that are not associated with highest accuracy—and sensitivity and specificity—they all wash out and you’re left with a minimal set of biomarkers that have maximum accuracy.

That is a really intense and highly technical process. It’s unique to IV Bioholdings, which is the bio innovation studio that Mammogen is a part of and Liquid Biosciences is associated with. By approaching large datasets in this fashion, we’re able to get a far more robust understanding of the biology behind whatever disease state it is we’re looking at. This capability is disease state agnostic, it does not have to be oncology. This platform has been applied to Alzheimer’s, autism, Parkinson’s and addiction behavior.

However, for our flagship program at Mammogen, it allowed us to mine publicly available datasets in an extremely accelerated manner. It allowed us to see things that other people have never seen because we’re getting such a far more robust understanding of the biology and that’s very important.

Then secondary to that—if you put on your commercial brain—it allows us to create a very valuable intellectual property moat around what we’re developing, because this process is repeated over and over again. So multiple generations of evolution, which give us multiple sets of biomarkers that we move forward into clinical stage validation.

That protects our intellectual property, it accelerates our clinical development timelines, and it allows us to get products to patients in a hyper efficient manner. Statistically, the average diagnostic company takes five to seven years and about $18 million to get to the point where they have a set of biomarkers that have been analytically validated.

Mammogen did it in 22 days for a tiny fraction of that.

MTDHN: Wow. What does that mean for the future of Mammogen?

LC M: It means we are hyper efficient in our R&D process which translates to extremely reduced costs in development, and reduced costs in commercialization.

We don’t need to charge $3,000 for our tests to make a profit as a company. We can make a very reasonably priced test that is accurate, safe, sensitive, specific and get it into the hands of our women in a fraction of the time as compared to other diagnostic companies.

MTDHN: Your name implies mammograms for breast cancer, but what other medical conditions do you focus on?

LCM : Breast cancer is our flagship program. Beyond that, we are beginning development for endometriosis and other areas within women’s healthcare that have an unmet clinical need.

For endometriosis, for example, there is no way to definitively diagnose it except through a very invasive biopsy. The average woman suffers for 17 years before she’s accurately diagnosed. There’s no reason for that.

What we’re developing is a very simple liquid biopsy test that a woman can take to tell her whether or not she has endometriosis.

I’m someone who suffered from endometriosis. Having my family and living with the symptoms was terribly difficult. I was misdiagnosed over and over again. All of the time, resources, money, unnecessary spending and the physical and mental anguish that comes with being undiagnosed with a painful disease was very difficult.

Mammogen is focusing on areas like early detection of breast cancer, endometriosis detection and other issues that are traditionally very difficult to diagnose. These liquid biopsy tests are going to be simple to administer and completely noninvasive.

MTDHN: How will people go about getting this test when it is available? How will payers be involved?

LCM: P eople will be able to visit their provider who can order the test.

With payers there is still a huge disconnect with diagnostic innovation and recognizing the value of said diagnostics. It can be difficult for diagnostic companies in the beginning to span that gap, which is why I think it is so important to consider non-traditional models that get valuable diagnostics into the hands of patients on an accelerated timeline.

Now, I want to be clear I am not saying that we will not do all of the clinical trials, and all of the scientific validation necessary to satisfy payers and physicians and publication needs.

What I am saying is I believe there are other ways to bring a product to market aside from the traditional go through the payer route, which we will do, but we are also actively exploring other safe meaningful ways to get this product into the hands of patients.

MTDHN: Are you working with any advocacy organizations?

LCM: A big part of what we are building at Mammogen is based around community.

I’m a big believer that community engagement fuels market adoption and market adoption fuels the community.

We are actively engaging with other companies that are also focusing on innovative ways to treat either breast cancer and or the lasting effects of breast cancer. We are connecting with creators of everything from exercise routines to a company called Brilliantly, that just launched a breast warmer that fits right into breast cancer survivors’ bras after reconstructive surgery.

We were featured on a podcast that the founder of Mammogen and I did with Matthew Zachary, who is a tremendous advocate for all things oncology. We’re spending a lot of time working with him and his company called OffScrip Media to engage with our community, patients, survivors and advocacy groups.

MTDHN: Are you connecting with women in underserved communities?

LCM : Yes, that is a huge part of our organization. There are underserved women under 40 who struggle to get mammograms, which are important because women under 40 have the fastest growing rates of incidence.

There are also underserved communities where access to healthcare is not available because of age, race or ethnic background.

We are spending quite a bit of time to make sure those communities are represented fully in our clinical stage validation work so that we can, if necessary, create a test that is specific to certain populations. Currently, however, our science has proven effective for all women, regardless of age, ethnicity, stage of disease or genetic predisposition.

These are all things that we’re thinking about every single day as we prepare to bring these early detection tests to market.

MTDHN: Can you tell the readers how the company is funded, what your plans are, the size of your organization, etc.?

LCM: We are privately held and we just closed our $2 million seed round . That $2 million gets us through the next 12 to 18 months.

Mammogen is part of a bio innovation studio called IV Bioholdings, founded by Marty Keiser. IV Bioholdings has just opened the first round of fundraising at the studio level, as a means to provide capital to the three child companies below it.

Our process is hyper efficient, not just at Mammogen but across the other companies within the innovation studio. With this efficiency, the bottleneck is not R&D like it is for the rest of the industry, the bottleneck can then become financing. This approach eliminates that issue for the 3 companies within IV BioHoldings by providing capital to reach specific inflection points, which, in turn, make traditional fundraising more successful.

Mammogen will be raising a Series A round as well, of which planning and outreach has already begun.

MTDHN: How do you differentiate yourself from some of the other companies that are focused on women’s health?

LCM : Mammogen is proud to be a women’s health company lead by women, which is something unique in the industry.

I can use my healthcare experiences as a woman to help others. Knowing what it feels like to have endometriosis, to struggle for years to get diagnosed, and then to have lived the entire journey through hysterectomy is an advantage.

Another differentiator is our technology. We are looking at RNA when most of the rest of the world is looking at DNA. That is exceedingly important because RNA—the language of cells—is the key to early detection.

When you can listen in on what the cells are doing, as they are healthy, living and thriving, and or adapting to the introduction of disease, then you get earlier information. When information comes from the tumor not the patient, as is the case in DNA, you can’t collect any of that information until the tumor cell is dying, which is why DNA technologies have been wonderful at later stager applications like patient stratification or targeted therapy, but struggle in screening or early detection. RNA, however, is being released by all healthy living cells, as well as disease cells within a patient’s body all day, every day. You get earlier, better and more information, which is a huge distinguisher. RNA allows us to learn about the biology of the patient, not just the tumor.

Finally, Mammogen’s engagement with the community is a competitive advantage. The first thing I did when I took this job was spend over 50 hours talking to breast cancer patients and survivors and their families to understand the patient population I’m serving.

Sitting with these patients and hearing their stories, identifying the gaps in care and crying as they talk about it, is not the same as market research.

MTDHN: What does your growth pattern look like?

LCM: We are pre-revenue. We are in clinical validation stages right now with our strategic lab partner, P4 Diagnostix. This collaboration extends from assay development through commercialization, and further preserves our hyper efficient model.

The goal is to have this test launched in 2023. That would be less than three years from the inception of the company, which is tremendously impressive.

How Liquid Biopsy Holds Promise for Early Detection of Breast Cancer with Marty Keiser & Liz Cormier-May, Mammogen, Inc.

Fri, 08 Oct 2021 02:51:09 GMT

"Woman-led Mammogen Inc. is looking for breast cancers in a whole new way: using liquid biopsy to detect cancers far earlier, for more women, and with greater accuracy than traditional mammograms. They're also passionate about building a community to support women well beyond their initial diagnosis. A special look at the promising future for earlier breast cancer detection, in recognition of Breast Cancer Awareness Month!"

IV BioHoldings Debuts Liquid Biopsy Portfolio; Partners with P4 Diagnostix to Scale Commercialization of Non-Invasive Lung, Liver and Breast Diagnostics

Eric@adsneeded.com (Eric Kristiansen) — Wed, 22 Sep 2021 16:30:08 GMT

Bio innovation studio behind liquid biopsy companies LiquidLung, HepGene, and Mammogen, comes out of stealth with eight clinical-ready diagnostics

Formed to make early detection, diagnosis and treatment of pulmonary, metabolic, and women's health diseases easier and more precise

Strikes P4 partnership to unlock market potential for non-invasive lung, liver and breast diagnostics positioned to positively impact 220 million Americans and over one billion globally

Newport Beach, Calif – September 22, 2021 – IV BioHoldings (IVBH) has announced today the public launch of its bio innovation studio, debuting with a portfolio of liquid biopsy companies, including LiquidLung, Inc., HepGene, Inc. and Mammogen, Inc. Collectively, the IVBH companies comprise eight clinical-ready diagnostics, spanning the care continuum for lung cancer, non-alcoholic fatty liver disease (NAFLD) and breast cancer, respectively.

IVBH has also announced today its partnership with P4 Diagnostix® (P4), a leader in diagnostic pathology, to fast-track commercial efforts of molecular diagnostic tests and meet clinical demand for earlier, easier and more precise detection, diagnosis and treatment of pulmonary, metabolic, and women's health disease. Offering best-in-class testing services and proprietary healthcare informatics, P4 will serve as the exclusive laboratory partner for all clinical assay development and clinical validation across the lung cancer, NAFLD and breast cancer programs for each of the IVBH companies.

“What we’re seeing out of the IVBH ecosystem is platform test development capabilities that are years ahead of traditional test development in the liquid biopsy space, representing an opportunity for P4 to get on the ground floor of this dynamic area of molecular medicine,” said Marcus Cognetti, Co-Founder of P4. “By partnering across the IVBH portfolio, we’re providing an industry-first opportunity to scale the speed and rate at which non-invasive diagnostics are made available to the millions of people for whom this testing is not available or are underserved by the existing standards of care. The novelty of the science, strength of the data, and competitive intellectual property built around these existing indications is quite astonishing, and is a testament to the efficiency of the IVBH business model and its progressive approach to R&D.”

IVBH was founded in 2018 by Marty Keiser, with the vision of dramatically reducing the time, cost and risk associated with healthcare innovation through unique applications of data analysis using advanced technology. Its business model was purpose-built to accelerate value creation of novel intellectual property by allowing each of its disease-specific companies to leverage shared resources and tap into strategic partnerships formed by the studio.

In just over two years since launching LiquidLung, the first home-grown property to emerge from the studio, and one month after announcing the closing of a $2M seed round at its women’s health startup, Mammogen, the studio has now emerged from stealth with its portfolio of intellectual property positioned to address unmet clinical needs for 220 million Americans and over one billion people globally.

IVBH partnered with Liquid Biosciences (LBS), whose Emerge bio-analytics platform has been radically reducing diagnostic and drug development time, cost and risk for a decade. IVBH and LBS collaborated on novel biomarker discovery and validation to develop the following liquid biopsy solutions:

LiquidLung, Inc. – Non-invasive early detection, confirmatory diagnosis, and histological typing and subtyping of lung cancer. In a study conducted in peripheral whole blood for lung cancer detection, the technology achieved 97% sensitivity, 85% specificity, including 100% detection of patients with stage I lung cancer, without the use of any demographics, clinical risk-factors, or radiological data.

HepGene, Inc. – Non-invasive early detection of NAFL, classification of NAFL versus non alcoholic steatohepatitis (NASH), and definitive diagnosis of NASH. HepGene’s technology was validated across a diverse range of tissue types and biofluids (including blood), achieving 92% sensitivity, 97% specificity for early detection of NAFL and 94% sensitivity, 86% specificity for definitive diagnosis of NASH. The company IP also includes a proprietary portfolio of promising novel therapeutic targets for the treatment of NASH, which emerged from robust in vivo analysis of diseased patients and is supported by strong proof-of-principle that establish and validate biological plausibility.

Mammogen, Inc. – Non-invasive early detection and confirmatory diagnosis of breast cancer. Mammogen’s core technology, validated across peripheral blood mononuclear cells as well as saliva, is initially geared towards women under 40 and women over 55, two populations of women who are underserved by existing screening guidelines and current standards of care for breast cancer. Optimizing for women under 40, Mammogen’s technology achieved 93% sensitivity, 97% specificity. Optimizing for women over 55, the technology achieved 97% sensitivity, 87% specificity. Results were achieved without the use of any demographics or clinical risk-factors.

The introduction to P4 was made by Elizabeth Cormier-May, CEO of Mammogen and commercialization expert within the inner echelons of the IVBH studio, who has had a longstanding working relationship with the molecular lab throughout the course of her near twenty-year career in diagnostics.

“P4’s repeated success in diagnostic commercialization, seven CLIA certified laboratories strategically located across the US, and its proprietary IT solutions enabling electronic health record (EHR) integration, ensures that our clinical and commercial phases of development will be consistent with the efficiency of our model, making them the ideal partner for IVBH,” stated Cormier-May.

“What normally takes the diagnostics industry at least six years to accomplish on a per product basis, we did for eight clinical-ready diagnostic products in just over two years,” said IVBH founder and CEO Marty Keiser. “There’s no question that accelerated R&D timelines, and the corresponding reduction in risk associated with over 200 novel scientific discoveries across the lung, liver and breast programs, were a direct result of IVBH’s powerful partnership model and intentional application of exponential technologies such as that of our partners at LBS. With the addition of P4, we’re able to progress from R&D to commercialization with a level of speed, efficiency and quality that all patients deserve.” IVBH is now scaling to support its flagship lung, liver and breast programs through clinical development and commercialization. Other plans on the horizon include a focus on pipeline expansion across pulmonary, metabolic and women’s health disease, and incubation of future company creations.

For more information on IV BioHoldings, visit www.ivbh.studio . To explore partnership opportunities, email info@ivbh.studio .

h ttps://www.uspreventiveservicestaskforce.org/uspstf/recommendation/lung-cancer-screening ,

https://www.the-nash-education-program.com ,

h ttps://www.statista.com/statistics/241488/population-of the-us-by-sex-and-age/

About IV BioHoldings

We are a bio innovation studio specializing in de novo company creation at the intersection of diagnostics and life sciences. We take a multi-disciplinary approach to building companies; cross-pollinating ideas and experience across a variety of industries, breaking down silos, upending the healthcare R&D process, and rethinking the startup model. We leverage powerful partnerships and advanced analytical science to provide greater insight into human biology in order to radically improve the detection, diagnosis and treatment of disease. The current IVBH ecosystem comprises three transformative bio startups, including LiquidLung, Inc., HepGene, Inc., and Mammogen, Inc., focused on pulmonary disease, metabolic disease, and women's health, respectively. For more information visit www.ivbh.studio .

About P4 Diagnostix®

P4 Diagnostix® is a network of several nationally recognized testing and diagnostic facilities integrated into one unified lab services organization, offering clients unparalleled access to connectivity, healthcare resources and consultative partnerships. P4 is made up of these industry-leading companies: Theranostix, Long Island Pathology, Platinum Pathology, Metamark Laboratories and P4 Clinical. P4's progressive integration of diagnostic testing and office workflow is rooted in partnership with VitalAxis, an industry leader in the delivery of healthcare informatics. For more information visit www.p4dx.com .

About Liquid Biosciences

Liquid Biosciences radically reduces diagnostic and drug development risk, time, and cost, from pre clinical research through regulatory approval. Our Emerge bio-analytics platform agnostically discovers and models the nonlinear dynamics of how biology, behavior, and circumstances interact to drive patient outcomes. Our mathematical evolution technology goes beyond artificial intelligence's capabilities, and has produced superior accuracy, novel insights, and explainability in every head-to-head comparison with other analytic methods. Liquid Biosciences' clients are major biopharma firms, diagnostic companies, and world-class research institutions. We've completed over 180 major analytic projects across 45 diseases, using the full spectrum of clinical trial, real-world, and multi-omics biomarker data. For more information about Liquid Biosciences, visit www.liquidbiosciences.com .

Our Founder, Marty Keiser, and our CEO, Elizabeth Cormier-May, were guests on Matthew Zachary’s OffScrip Media podcast, Out of Patients.

Eric@adsneeded.com (Eric Kristiansen) — Tue, 27 Jul 2021 16:36:56 GMT

Listen to Marty and Liz offer their thoughts and commercial insights into the diagnostics market! Approaching traditional hurdles with innovative solutions is the ONLY way to move the needle forward for our patients!

Women's Health Startup Mammogen, Inc. Announces Oversubscribed Seed Round and the Debut of genTRU™ Liquid Biopsy Platform

Eric@adsneeded.com (Eric Kristiansen) — Thu, 01 Jul 2021 18:15:15 GMT

ALISO VIEJO, Calif, June 30, 2021 /PRNewswire/ -- Mammogen, a female-led women's health startup, has announced the closing of its $2 million series-seed round of equity financing. The round was oversubscribed by a diverse group of high-net-worth investors, comprising 52% women, members of the LGBTQ+ community, and veterans from the US Armed Forces, according to the company.

"The vast diversity across our investor base is evidence that the world is ready for a truly differentiated women's health narrative," stated Mammogen Chief Executive Officer, Elizabeth Cormier-May. She went on to say, "We are uniquely integrating data, science and the lived experiences from the patients that we serve into all ongoing product development efforts related to our flagship breast cancer program. Our objective is to detect earlier, diagnose easier and treat more comprehensively for the nearly 100M women who are currently underserved by existing standards of care."

"Our community is equally as important to us as our science."

"Most importantly, we are doing all of this with the overwhelming support of our community from day one. These differentiators not only resonated deeply with our shareholders, but they will significantly contribute towards our objective of becoming the world's leading powerhouse in women's health," continued Cormier-May.

In addition to its recent funding announcement, the company is introducing its proprietary genTRU™ liquid biopsy platform, a novel RNA-based technology that will house the company's suite of women's health diagnostics, with its flagship non-invasive breast cancer offering falling under the genTRU breast™ nomenclature. The genTRU breast™ program consists of two initial diagnostic tests positioned to unlock screening and reduce negative biopsies for large populations of women who are not being regularly or reliably screened, based on recommended screening guidelines and limitations of existing technologies. To date, the company's technology has been extensively validated in blood, as well as saliva, and has demonstrated statistical significance toward providing measurable improvement upon current standards of care.

"When you look at the unmet clinical needs that we are addressing with our highly advanced genTRU™ platform, as well as our focus on addressing the often-unspoken personal needs associated with so many women's health issues, it's very clear that our community is equally as important to us as our science," stated Mammogen founder & IV BioHoldings (IVBH) CEO, Marty Keiser.

"While everyone else is talking end-to-end care, Mammogen is building an end-to-never-end community. The idea is for our community to fuel market adoption and for market adoption to fuel our community, creating a positive feedback loop that both serves patients and accelerates growth," Keiser continued.

Proceeds from the latest round of financing will fund ongoing clinical development efforts for the genTRU breast™ program, secure strategic partnerships and alliances and further strengthen and expand the company's existing intellectual property portfolio.

About Mammogen

Mammogen is a female-led biotechnology company focused on meaningfully improving the detection, diagnosis and treatment of women's health-related diseases, and creating an end-to-never-end community for women around the world. Mammogen is centered around its proprietary genTRU™ liquid biopsy platform. The company's flagship genTRU breast™ program leverages novel messenger RNA (mRNA) technology to non-invasively detect and diagnosis breast cancer. The genTRU breast™ offering is positioned to unlock regular and reliable screening for millions of women around the world and eliminate many negative invasive biopsy procedures. The company's proprietary multi-gene expression signature for breast cancer detection has been extensively validated in blood, as well as saliva, and has shown statistical significance towards providing measurable improvement upon current standards of care. Mammogen's product pipeline consists of an array of non-invasive prognostics and diagnostics for additional diseases that affect some-, mostly-, or only-women. For more information visit www.mammogen.bio .

About IV BioHoldings

IV Bioholdings (IVBH) is a bio innovation studio that takes a multi-disciplinary approach to building companies; cross-pollinating ideas and experience across a variety of industries, breaking down silos, upending the healthcare R&D process, and rethinking the startup model. The studio uses advanced analytical science to provide greater insight into human biology and radically improve the detection, diagnosis, and treatment of disease. The current IVBH ecosystem comprises three transformative bio startups, including LiquidLung, HepGene and Mammogen, focused on pulmonary disease, metabolic disease, and women's health, respectively. For more information visit www.ivbh.studio .

MEDIA CONTACT: info@mammogen.bio

With its advanced offerings, Mammogen specializes in improving the detection, diagnosis, and treatment of breast cancer

Eric@adsneeded.com (Eric Kristiansen) — Tue, 08 Jun 2021 16:29:00 GMT

Mammogen enhances detection diagnosis treatment of breast cancer.

Brilliantly.co IG Live with Mammogen.bio

Eric@adsneeded.com (Eric Kristiansen) — Wed, 02 Jun 2021 16:41:24 GMT

Mammogen is a woman-led biotechnology company and we're using data, tech, science and personal experience to shatter complacency.

Founder, Marty Keiser, and CEO, Liz Cormier-May, share their plans to create an end-to-never-end community for women with breast cancer.

International Life Sciences Awards 2021

Eric@adsneeded.com (Eric Kristiansen) — Wed, 12 May 2021 16:35:03 GMT

Best Breast Cancer Detection Technology Company – USA

Mammogen is the third of three companies operating under the umbrella of a bio innovation studio called IVBioHoldings. Mammogen is a company incubated with a simple mission that has not and will never waiver: to meaningfully improve every aspect of the women’s health market, and to do so by building a company with an overwhelming presence of women at every level.

Veteran Biotechnology Executive Elizabeth Cormier-May Recruited to Lead Women's Health Startup Mammogen Inc.

Eric@adsneeded.com (Eric Kristiansen) — Thu, 04 Feb 2021 23:23:19 GMT

ALISO VIEJO, Calif., Feb. 4, 2021 /PRNewswire/ -- Mammogen, Inc. , a women's health startup born at the intersection of data, technology and science, and Bench International, a leading global executive search firm, jointly announce the appointment of Elizabeth Cormier-May as Chief Executive Officer and member of the board of directors of Mammogen. She will begin her new role on March 1st, 2021.

In her new role, Cormier-May will lead efforts to develop, validate and commercialize the company's flagship liquid biopsy program for breast cancer, while working to position Mammogen as a global leader in women's health. The company has developed a proprietary methodology for early cancer detection using novel messenger RNA (mRNA) biomarkers, which has shown statistical significance towards providing measurable improvement upon current standards of care.

"When women think of their physical, mental and emotional health, I want Mammogen to be the first, second, and third thing that comes to mind," said Ms. Cormier-May. "Mammogen is working to detect earlier, diagnose easier, treat better, and to support all women throughout the life-long battle that comes with survivorship. Providing end-to-end care is good, but we think an end-to-never-end community is better."

"Providing end-to-end care is good, but we think an end-to-never-end community is better."

Mammogen's core technology is a non-invasive screening solution intended for all women, but particularly for the under-40 population who aren't eligible for annual mammography and the 55+ population who are only recommended for mammography every other year. "Mammogen's technology will provide regular and reliable screening and diagnostic tools for tens of millions of women who are grossly underserved by current standards of care," said the incoming CEO. "I am extremely excited to build off of Mammogen's strong scientific foundation and speed this innovation to market, so that we can get more women screened earlier and arm clinicians with actionable insights about their patients."

Ms. Cormier-May brings vast experience within medicinal chemistry, genetics, and both companion and molecular diagnostics while working with companies including Novartis Pharmaceuticals, Myriad Genetics, Qiagen, and Predictive Biosciences. Elizabeth built her career launching and selling diagnostic tests into the women's health, oncology and urology markets. During her tenure as Head of Commercial Operations at Exosome Dx (acquired by Bio-Techne), Elizabeth was responsible for building the infrastructure and defining the launch of the company's flagship diagnostic, ExoDx Prostate(IntelliScore).

"I am humbled by the fact that of all the opportunities in this space, Elizabeth chose Mammogen," stated company Founder and Chairman, Marty Keiser. "Denise (DeeDee) DeMan, the founder and CEO of Bench International, immediately connected with my passion for improving women's health and my vision to build Mammogen as a women-led organization. DeeDee not only brought us a top CEO, but she has also joined our board of directors, bringing extensive experience and connections in the life science community that will continue to add value at every stage of growth for Mammogen."

Mammogen is one of three joint venture companies established between IV BioHoldings (IVBH), a bio innovation studio founded by Keiser, and leading healthcare analytics provider, Liquid Biosciences. "When Marty first told me of his plans to apply his unique approach to venture creation to women's health, including finding ways to offer underserved women access to innovative technologies, it was obvious that people would be one of his greatest assets," said Ms. DeMan. "When you combine Elizabeth's experience in liquid biopsies and early-stage diagnostics, her track record in unlocking value for patients, payers and stakeholders, and her courageous and ambitious spirit, there is no question that we found the perfect person to build Mammogen into an industry leader in women's health."

About Mammogen

Mammogen is a female-led biotechnology company focused on meaningfully improving the detection, diagnosis and treatment of women's health-related diseases, and creating an end-to-never-end community for women around the world. Mammogen's flagship product is a liquid biopsy test that measures novel circulating messenger RNA (mRNA) biomarkers required for the non-invasive detection and diagnosis of breast cancer. The non-invasive test is positioned to unlock regular and reliable screening for millions of women around the world and eliminate many unnecessary biopsy procedures. The company's proprietary multi-gene expression signature for breast cancer detection has been extensively validated in blood, as well as saliva, and has shown statistical significance towards providing measurable improvement upon current standards of care. Mammogen's product pipeline consists of an array of non-invasive prognostics and diagnostics for breast cancer, ovarian cancer, endometriosis and other diseases that affect some-, mostly-, or only-women. For more information visit www.mammogen.bio .

About Bench International

Bench International is the oldest woman-founded executive search firm serving the Life Science and Healthcare sectors. The firm is also one of the most renowned experts in diversity recruitment at the board and executive level, as well as in R&D leadership. Bench's scorecard reflects over $150 billion in successful client exits, a 98% project completion record, with a 75% retention for five or more years. 33% of all leaders placed in Bench's 45+ year history have been gender and ethnically diverse. With headquarters in San Diego, California, and satellite offices in Los Angeles, New York, Boston, the United Kingdom and Switzerland, Bench is One Global Team, No Borders, No Boundaries and One Global Budget, thus mitigating internally competitive offices. For more information visit www.benchinternational.com .

About IV BioHoldings

IV BioHoldings (IVBH) is an innovation studio that specializes in de novo company creation exclusively within life sciences. The IVBH studio takes a multi-disciplinary approach to building companies; cross-pollinating ideas and experience across a variety of industries, breaking down silos, upending the healthcare R&D process, and rethinking the startup model. The studio uses advanced analytical science to provide greater insight into human biology and radically improve the detection, diagnosis, and treatment of disease. The current IVBH ecosystem comprises three transformative bio startups, including LiquidLung, HepGene and Mammogen, focused on pulmonary disease, metabolic disease, and women's health, respectively. For more information visit www.ivbh.studio .

About Liquid Biosciences

Liquid Biosciences (LBS) radically reduces diagnostic and drug development risk, time, and cost, from pre-clinical research through regulatory approval. LBS' Emerge bio-analytics platform agnostically discovers and models the nonlinear dynamics of how biology, behavior, and circumstances interact to drive patient outcomes. Our mathematical evolution technology goes beyond artificial intelligence's capabilities, and has produced superior accuracy, novel insights, and explainability in every head-to-head comparison with other analytic methods. Liquid Biosciences' clients are major biopharma firms, diagnostic companies, and world-class research institutions. We've completed over 165 major analytic projects across 44 diseases, using the full spectrum of clinical trial, real-world, and multi-omics biomarker data. For more information about Liquid Biosciences visit www.liquidbiosciences.com .

CONTACT: info@mammogen.bio

SOURCE Mammogen

mammogen

Mammogen Taps Life Sciences Leadership Architect, Denise "DeeDee" DeMan, as Chairwoman of the Board of Directors

S2E18: Early Cancer Detection, Reimagined. Don't Be Dense, Get Checked with Liz Cormier-May, CEO of Mammogen

Safe & Green Holdings Corp. Taps Global Life Sciences & Diagnostics Executive, Elizabeth Cormier-May, to Join Company Board of Directors

Mammogen Inc. CEO Elizabeth Cormier-May Wins Illustrious Award with Business Worldwide Magazine

About Business Worldwide Magazine

Mammogen and Brilliantly Continue their Commitment to the Breast Cancer Community with Brilliantly Warm Giveaway

About Brilliantly

About Mammogen

Mammogen Touts Growing List of 2021 Awards and Recognitions for its Work in Women’s Health and Breast Cancer Diagnostics

About Mammogen

About P4 Diagnostix®

About Brilliantly

Mammogen and Brilliantly Combine Forces to Advance Community Efforts for Breast Cancer Previvors and Survivors

Female-led women’s health companies announce comprehensive partnership designed to empower breast cancer community

About Mammogen

About Brilliantly

SPOTLIGHT INTERVIEW: LIZ CORMIER-MAY, CEO, MAMMOGEN, INC.

About Elizabeth Cormier-May

About Mammogen

How Liquid Biopsy Holds Promise for Early Detection of Breast Cancer with Marty Keiser & Liz Cormier-May, Mammogen, Inc.

IV BioHoldings Debuts Liquid Biopsy Portfolio; Partners with P4 Diagnostix to Scale Commercialization of Non-Invasive Lung, Liver and Breast Diagnostics

About IV BioHoldings

About P4 Diagnostix®

About Liquid Biosciences

Our Founder, Marty Keiser, and our CEO, Elizabeth Cormier-May, were guests on Matthew Zachary’s OffScrip Media podcast, Out of Patients.

Women's Health Startup Mammogen, Inc. Announces Oversubscribed Seed Round and the Debut of genTRU™ Liquid Biopsy Platform

About Mammogen

About IV BioHoldings

With its advanced offerings, Mammogen specializes in improving the detection, diagnosis, and treatment of breast cancer

Brilliantly.co IG Live with Mammogen.bio

Mammogen is a woman-led biotechnology company and we're using data, tech, science and personal experience to shatter complacency. Founder, Marty Keiser, and CEO, Liz Cormier-May, share their plans to create an end-to-never-end community for women with breast cancer.

International Life Sciences Awards 2021

Best Breast Cancer Detection Technology Company – USA

Veteran Biotechnology Executive Elizabeth Cormier-May Recruited to Lead Women's Health Startup Mammogen Inc.

Related Links

Mammogen is a woman-led biotechnology company and we're using data, tech, science and personal experience to shatter complacency.

Founder, Marty Keiser, and CEO, Liz Cormier-May, share their plans to create an end-to-never-end community for women with breast cancer.